https://www.selleckchem.com/products/bso-l-buthionine-s-r-sulfoximine.html Menstrual blood loss (140.1 mL vs. 127.02 mL; P = 0.44) and mean fibroid volume reduction (47.5 cm3 vs. 36.0 cm3; P = 0.17) were similar between Black and White women at 12 months. Although not statistically significant, the intraoperative total blood loss and uterine blood loss was lower in Black women than White women, despite greater operative time (160 minutes vs. 137 minutes; P = 0.09). Conclusions These results are promising in providing an alternative uterine-sparing option for Black women and may help to provide a minimally invasive option that can address some of the racial inequities in care for Black women with UF. Established breast cancer risk factors, such as hormone replacement therapy and reproductive history, are thought to act by increasing estrogen and progesterone (P4) activity. We aimed to use screening data to identify chemicals that increase the synthesis of estradiol (E2) or P4 and evaluate potential risks. Using data from a high-throughput (HT) steroidogenesis assay developed for the U.S. Environmental Protection Agency (EPA) ToxCast program, we identified chemicals that increased estradiol (E2-up) or progesterone (P4-up) in human H295R adrenocortical carcinoma cells. We prioritized chemicals by their activity. We compiled studies and assessments about carcinogenicity and reproductive/developmental (repro/dev) toxicity. We identified exposure sources and predicted intakes from the U.S. EPA's ExpoCast. We found 296 chemicals increased E2 (182) or P4 (185), with 71 chemicals increasing both. data often showed effects consistent with this mechanism. Of the E2- and P4-up chemicals, about 30r drugs have not been evaluated for carcinogenic potential and are priorities for study and exposure reduction. https//doi.org/10.1289/EHP8608. The U.S. EPA's in vitro screening data identified several hundred chemicals that should be considered as potential risk factors for breast canc